BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260528T190000
DTEND;TZID=Africa/Nairobi:20260528T203000
DTSTAMP:20260529T182745Z
CREATED:20260525T190142Z
LAST-MODIFIED:20260529T182745Z
UID:41658-1779994800-1780000200@kesho-kenya.org
SUMMARY:The Brain Tumour Journey
DESCRIPTION:Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa\nModerator: Mr. David L. Oluoch-Olunya \nThe Brain Tumour Journey brought together neurosurgery\, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum\, from first symptoms and referral to surgery\, pathology\, oncology treatment\, rehabilitation\, follow-up and family support. \nDr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty\, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes\, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging\, surgery\, pathology\, endocrine review\, oncology care and long-term follow-up without being lost in fragmented systems. \nDr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data\, suggesting delays in diagnosis and referral. Children may present with persistent headaches\, vomiting\, visual changes\, seizures\, gait or coordination problems\, abnormal head growth\, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion\, especially when symptoms are progressive\, recurrent or not responding as expected. \nThe session also examined Kenyan system-level challenges\, including limited access to timely imaging\, prolonged pathways between surgery and radiotherapy\, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics\, where patients and families can receive coordinated input from neurosurgery\, oncology\, radiology\, pathology\, rehabilitation\, counselling and navigation teams within a more structured care pathway. \nDr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis\, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context\, radiology\, histology\, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling\, stronger neuropathology capacity\, expanded diagnostic panels\, molecular testing access and regular multidisciplinary tumour board discussions. \nAcross the session\, the message was clear: improving brain tumour outcomes requires coordinated systems\, not isolated excellence. Timely diagnosis\, accurate pathology\, surgical expertise\, oncology planning\, patient navigation\, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound\, humane and sustainable. \nKey Takeaways\n\nBrain tumour care is a journey\, not a single event. Patients often require coordinated input across imaging\, surgery\, pathology\, oncology treatment\, rehabilitation and follow-up.\nPatient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments\, delayed reviews or incomplete follow-up.\nChildren may present with subtle or progressive symptoms. Persistent headaches\, seizures\, visual changes\, gait problems\, behavioural changes or endocrine symptoms should prompt a high index of suspicion.\nMultidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.\nAccurate diagnosis depends on integrated pathology. Histology remains central\, but immunohistochemistry and molecular testing increasingly guide classification\, prognosis and treatment options.\nKenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways\, registries\, specialist training\, diagnostic capacity\, molecular testing access and survivorship systems remain key priorities.
URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-28-at-3.56.29-PM-1-e1780079236823.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260611T190000
DTEND;TZID=Africa/Nairobi:20260611T203000
DTSTAMP:20260629T093247Z
CREATED:20260609T080719Z
LAST-MODIFIED:20260629T093247Z
UID:41725-1781204400-1781209800@kesho-kenya.org
SUMMARY:Strengthening Haemato-Oncology Care
DESCRIPTION:STRENGTHENING HAEMATO-ONCOLOGY CARE THROUGH PALLIATIVE CARE AND RESEARCH EXCELLENCE \n\nModerator: Prof. John Weru\nSpeaker: Prof. Sayed Karar\nDate: 11 June 2026\n\nThis session examined palliative care as a critical component of quality and comprehensive haemato-oncology care. The discussion challenged the misconception that palliative care belongs only at the end of life and instead presented it as an added layer of support that can be introduced early\, alongside active treatment. \nA central theme was the distinction between palliative care and hospice. Prof. Sayed Karar emphasized that palliative care can support patients and families at any stage of serious illness\, including during chemotherapy\, radiotherapy or other disease directed treatment. Hospice care\, by contrast\, is generally associated with advanced disease when curative options are no longer appropriate. The discussion framed palliative care as a holistic service that addresses pain\, symptoms\, psychological distress\, spiritual concerns\, social needs and family burden. \nThe session also situated palliative care within the African and Kenyan context. Prof. Karar highlighted the large unmet need for palliative care across the continent\, the uneven availability of services\, limited access to opioids and the continued underuse of affordable medicines such as morphine. Local studies were used to show how research can change practice\, including ICU trigger models that help identify patients who should receive timely palliative care review. \nThrough case scenarios\, the discussion explored difficult conversations\, symptom control\, prognostication\, end of life feeding\, dialysis decisions\, family conflict and the role of faith and hope in care decisions. Practical tools such as the SPIKES framework were discussed as a way to support clear\, compassionate communication. The session also reinforced the importance of identifying the appropriate decision maker\, using plain language and allowing families time to process serious news. \nAcross the session\, a consistent message emerged: palliative care is not about withdrawing care. It is about strengthening care\, relieving suffering\, supporting decision making and helping patients and families navigate serious illness with dignity. \nKey Takeaways \n\nPalliative care should be introduced early and can run alongside active haemato-oncology treatment.\nHospice and palliative care are related but not the same; palliative care is appropriate at any stage of serious illness.\nPain control requires careful assessment\, stepwise treatment\, safe opioid use and attention to side effects such as constipation.\nDifficult conversations need preparation\, privacy\, clear language\, empathy and structured follow up.\nLocal palliative care research can influence practice\, including the use of triggers to identify patients who need timely review.\nEvery clinician should have basic palliative care skills\, especially in settings where specialist services are limited.
URL:https://kesho-kenya.org/event/strengthening-haemato-oncology-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-09-at-6.28.14-AM-e1780992584937.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260618T190000
DTEND;TZID=Africa/Nairobi:20260618T203000
DTSTAMP:20260617T133652Z
CREATED:20260617T080505Z
LAST-MODIFIED:20260617T133652Z
UID:41730-1781809200-1781814600@kesho-kenya.org
SUMMARY:Nutrition into Oncology
DESCRIPTION:Integrating Nutrition into Oncology Practice \nFueling Better Outcomes \n📅 Date: 18th June 2026\n🕖 Time: 7 PM – 8:30 PM EAT\n🏅 CPD Accredited \nMODERATOR\nKennedy Okinda\nOncology Nutrition Specialist\, Mwai Kibaki Referral Hospital \nSPEAKER\nNjoki Karanja\nOncology Nutrition Specialist\nNutrition in Cancer Care: From Treatment to Recovery \nSPEAKER\nDr. Andrew Odhiambo\nMedical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\nThe Clinical Impact of Nutrition on Cancer Outcomes
URL:https://kesho-kenya.org/event/nutrition-into-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-17-at-2.19.27-PM-1-e1781703392442.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260625T193000
DTEND;TZID=Africa/Nairobi:20260625T203000
DTSTAMP:20260629T093106Z
CREATED:20260624T084816Z
LAST-MODIFIED:20260629T093106Z
UID:41736-1782415800-1782419400@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:SICKLE CELL DISEASE: FROM NEWBORN DETECTION TO LONG-TERM OUTCOMES \n\nModerator: Dr. Fatmah Abdallah\nSpeakers: Dr. Bernard Awuonda and Dr. Sophie Uyoga\n\nThis session examined sickle cell disease through the full patient pathway\, from newborn detection and early diagnosis to long-term care\, survival and health-system readiness. \nDr. Bernard Awuonda opened the session by situating sickle cell disease as an inherited haemoglobin disorder and emphasising the importance of public education in reducing stigma. The discussion highlighted that sickle cell disease is not contagious and that clear communication with families and communities is essential for improving understanding\, genetic counselling and health-seeking behaviour. \nA major focus of the session was the burden of sickle cell disease in sub-Saharan Africa and Kenya. Dr. Awuonda noted that without timely intervention\, many children born with sickle cell disease in high-burden settings die before the age of five. This framed the case for newborn screening as a life-saving public health intervention\, rather than a specialist service alone. \nThe discussion explored screening modalities\, including point-of-care testing and laboratory-based approaches\, and highlighted the importance of linking screening to action. Early detection only improves outcomes when it is followed by caregiver education\, prophylactic care\, vaccination\, access to hydroxyurea where appropriate\, routine monitoring and clear referral pathways. \nDr. Sophie Uyoga shared experience from Kilifi\, where structured sickle cell care has combined clinical service delivery\, research\, patient follow-up and community engagement. The session highlighted how early testing\, routine monitoring\, access to hydroxyurea and caregiver education can improve survival and health-seeking behaviour. \nThe discussion also addressed the realities of long-term care\, including transition from paediatric to adult services\, psychosocial support\, affordability\, access to diagnostics\, transfusion planning and the importance of maintaining patients in care. The speakers emphasised that sickle cell disease should not be viewed as a death sentence. With early diagnosis\, structured follow-up and supportive systems\, patients can live fuller and longer lives. \nThe session reinforced the need to operationalise infant screening policy\, strengthen financing\, improve point-of-care capacity\, support data systems and build care pathways that connect newborn screening to lifelong care. \nKey Takeaways \n\nNewborn screening is critical for early identification and timely intervention in sickle cell disease.\nScreening must be linked to care\, including caregiver education\, prophylaxis\, vaccination\, routine monitoring and referral pathways.\nSickle cell disease is inherited and not contagious; community education remains important for reducing stigma.\nHydroxyurea\, routine monitoring and structured clinical follow-up can reduce complications and improve outcomes.\nTransition from paediatric to adult care requires stronger planning\, psychosocial support and retention strategies.\nPolicy\, financing\, data systems and point-of-care testing are essential for scaling sickle cell care across Kenya.
URL:https://kesho-kenya.org/event/sickle-cell-disease-4/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-23-at-10.10.49-AM-e1782290824589.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260709T190000
DTEND;TZID=Africa/Nairobi:20260709T203000
DTSTAMP:20260820T221134Z
CREATED:20260709T131009Z
LAST-MODIFIED:20260820T221134Z
UID:41811-1783623600-1783629000@kesho-kenya.org
SUMMARY:Management of Endometrial Cancer
DESCRIPTION:A Multidisciplinary Approach in the Management of Endometrial Cancer\n📅 9th July 2026\n⏰ 7PM – 8:30PM EAT \nJoin our expert panel:\n👨‍⚕️ Dr. Alfred Mokomba — Surgical Management and Risk Stratification\n👩‍⚕️ Dr. Catherine Nyongesa — Adjuvant Radiotherapy and Multidisciplinary Decision-Making\n🎙️ Moderated by Dr. Edward Sang \nSummary\nThis session examined endometrial cancer through a multidisciplinary lens\, linking early recognition and tissue diagnosis with surgical planning\, molecular risk classification and adjuvant treatment. \nA central theme was that treatment decisions increasingly depend on both traditional clinicopathological risk factors and tumour biology. Dr. Catherine Nyongesa reviewed stage\, grade\, depth of myometrial invasion\, lymphovascular space invasion and histology alongside the molecular groups defined by POLE mutation\, mismatch repair deficiency\, non-specific molecular profile and p53 abnormality. The discussion highlighted the practical value of mismatch repair and p53 immunohistochemistry\, which can help refine prognosis and guide treatment even where broader molecular testing is limited. \nRadiotherapy was presented as a risk-adapted component of care. Vaginal brachytherapy remains an important option for appropriately selected high-intermediate-risk patients\, while pelvic external beam radiotherapy is reserved for patients with greater pelvic or nodal risk. In higher-risk disease\, particularly stage III and p53-abnormal tumours\, chemotherapy and combined-modality approaches become increasingly relevant. \nDr. Alfred Mokomba focused on the diagnostic and surgical pathway. Postmenopausal bleeding was emphasised as a warning sign that should prompt investigation rather than reassurance. Endometrial sampling should establish histology before definitive surgery\, supported by imaging and appropriate staging. The extent of surgery and nodal assessment should then reflect disease stage\, histology and risk rather than following a uniform approach. \nAcross the session\, a consistent message emerged: endometrial cancer outcomes depend on getting the sequence right from the beginning. Early recognition\, accurate pathology\, risk-adapted surgery and coordinated adjuvant treatment allow the multidisciplinary team to individualise care while using available resources more effectively. \nKey Takeaways\n\nPostmenopausal bleeding should prompt timely investigation and tissue diagnosis.\nStage\, histology\, myometrial invasion\, lymphovascular invasion and molecular class all contribute to risk stratification.\nMismatch repair and p53 immunohistochemistry can provide clinically useful molecular information in resource-constrained settings.\nBrachytherapy\, pelvic radiotherapy and chemotherapy should be selected according to recurrence risk and tumour biology.\nSurgery should be planned within a multidisciplinary pathway and followed by review of final pathology and adjuvant needs.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/management-of-endometrial-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-09-at-4.04.41-PM-e1783603095456.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260716T190000
DTEND;TZID=Africa/Nairobi:20260716T203000
DTSTAMP:20260820T223526Z
CREATED:20260716T130048Z
LAST-MODIFIED:20260820T223526Z
UID:41816-1784228400-1784233800@kesho-kenya.org
SUMMARY:Advancing Cardio-Oncology in East Africa
DESCRIPTION:Advancing Cardio-Oncology in East Africa\nFrom Evidence to Everyday Practice \n\nDate: Thursday\, 16th July 2026\nTime: 7:00 PM – 8:30 PM EAT\n\nSpeakers \n\nDr. Anne Mwirigi; \n\nConsultant Haematologist & Assistant Professor | Aga Khan University Hospital\, Nairobi \n\nDr. Kieran Mwazo\n\nConsultant Cardiologist | Head of the Cardiology Division | Coast General Teaching and Referral Hospital\, Mombasa \n\nDr. Joseph Abuodha\n\nConsultant Medical Oncologist | Department of Haematology and Oncology | Aga Khan University Hospital\, Nairobi \nModerator \n\nProf. Arjun Ghosh\n\nConsultant Cardiologist | Barts Heart Centre\, St. Bartholomew’s Hospital | London & University College London Hospital \nSummary\nThis joint KESHO and Kenya Cardiac Society session explored how cardiovascular care can be integrated into cancer treatment from baseline assessment through active therapy and long-term survivorship. \nA central theme was that advances in cancer treatment have created a growing population of survivors while also expanding the range of potential cardiovascular effects. Dr. Anne Mwirigi set the scene by tracing the evolution of cancer therapy and highlighting how conventional chemotherapy\, targeted treatments and newer agents may affect the heart and vascular system in different ways. \nDr. Kieran Mwazo brought the discussion into the East African setting\, emphasising that cancer and cardiovascular disease share several risk factors and frequently coexist. Baseline assessment\, optimisation of existing cardiovascular disease and structured surveillance can help identify patients who need closer monitoring. ECG\, echocardiography\, global longitudinal strain\, cardiac biomarkers and advanced imaging were discussed as tools for detecting treatment-related injury before it becomes clinically advanced. \nThrough clinical cases\, Dr. Joseph Abuodha illustrated the complexity of decisions when cardiac toxicity develops during potentially life-prolonging cancer treatment. Bradyarrhythmias\, changes in cardiac function and suspected treatment-related myocardial injury highlighted the need to consider both oncological benefit and cardiovascular risk rather than automatically prioritising one condition over the other. Shared decision-making and close collaboration between specialties were repeatedly emphasised. \nThe session also looked beyond individual cases to the systems needed for cardio-oncology in Kenya and the region\, including integrated referral pathways\, locally adapted protocols\, workforce development and stronger data collection. Across the session\, a consistent message emerged: cardio-oncology is about protecting cardiovascular health without unnecessarily compromising effective cancer treatment. \nKey Takeaways\n\nCardiovascular assessment should begin before potentially cardiotoxic cancer treatment is started.\nModern cancer therapies can produce a broad range of cardiovascular effects beyond heart failure alone.\nRisk-adapted surveillance using ECG\, echocardiography\, strain and biomarkers can support earlier detection of toxicity.\nTreatment decisions should balance oncological benefit with cardiovascular risk through multidisciplinary and shared decision-making.\nEast Africa needs stronger cardio-oncology pathways\, training\, locally relevant protocols and regional data.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/advancing-cardio-oncology-in-east-africa/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-16-at-12.28.17-PM-e1784206835252.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260723T193000
DTEND;TZID=Africa/Nairobi:20260723T203000
DTSTAMP:20260820T222912Z
CREATED:20260721T125010Z
LAST-MODIFIED:20260820T222912Z
UID:41828-1784835000-1784838600@kesho-kenya.org
SUMMARY:Management of Treatment-Induced Neurotoxicity
DESCRIPTION:Management of Treatment-Induced Neurotoxicity session \n23rd July 2026\, 7–8:30 PM EAT\, \nFeaturing Dr. Herman Ekea\, Dr. Karishma Sharma\, and Dr. Juzar Hooker \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/management-of-treatment-induced-neurotoxicity/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-20-at-12.54.09-PM-4-e1784644283295.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260730T193000
DTEND;TZID=Africa/Nairobi:20260730T203000
DTSTAMP:20260820T222730Z
CREATED:20260728T131820Z
LAST-MODIFIED:20260820T222730Z
UID:41839-1785439800-1785443400@kesho-kenya.org
SUMMARY:Implementing Precision Oncology in LMICs
DESCRIPTION:Implementing Precision Oncology in LMICs:\nFrom Diagnosis to Clinical Decision-Making \nDate: 30th July 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker\nProf. Shahin Sayed\nAssociate Professor & Consultant\, Anatomical Pathology and Cytology\, Department of Pathology\, Medical College\, Aga Khan University; Chair & Laboratory Director. Pathology\, AKUH\, N\nThe Diagnostic Foundations of Precision Oncology: Pathology\, Biomarkers and Molecular Testing \nSpeaker\nProf. Chite Asirwa\nMedical Oncologist & Hematologist; CEO\, International Cancer Institute\nPrecision Oncology in LMICs: Current Landscape\, Clinical Application and the Road Ahead \nModerator\nProf. Nicholas Abinya\nConsultant Medical Oncologist\, Nairobi Hospital Cancer Centre \nSummary\nThis session examined what meaningful precision oncology looks like in low- and middle-income countries\, connecting clinical decision-making with pathology\, molecular diagnostics\, patient factors\, health-system capacity and access to treatment. \nA central theme was that precision oncology is broader than genomic sequencing. Prof. Chite Asirwa described it as the integration of clinical\, pathological\, molecular\, environmental and patient-specific information across diagnosis\, prognosis\, treatment selection and monitoring. Used well\, this approach can reduce ineffective empirical treatment\, limit unnecessary toxicity and direct limited resources towards interventions most likely to benefit the patient. \nProf. Shahin Sayed focused on the diagnostic foundations that make precision care possible. High-quality tissue\, correct fixation and handling\, validated assays\, quality assurance and clinically useful reporting all determine whether a molecular result can be trusted. The discussion reinforced that advanced testing cannot compensate for weak foundational pathology\, and that essential immunohistochemistry and biomarker testing remain an important starting point for many settings. \nThe session also addressed Africa’s underrepresentation in genomic datasets and the challenge of interpreting variants when locally relevant reference data are limited. Molecular results need clinical context and\, where possible\, multidisciplinary interpretation. Liquid biopsy and circulating tumour DNA were discussed as promising tools for selected applications\, but standardisation\, quality control and careful use remain important\, particularly when considering screening. \nImplementation was therefore framed as a phased health-system journey rather than a technology purchase. Strong pathology services\, reliable essential biomarkers\, regional molecular capacity\, better patient navigation\, financing and locally generated data must develop together. Across the session\, a consistent message emerged: precision oncology has greatest value when a reliable test leads to a clinically meaningful decision and an accessible treatment pathway. \nKey Takeaways\n\nPrecision oncology integrates clinical\, pathological\, molecular and patient-specific information rather than genomics alone.\nAccurate pathology\, specimen quality and laboratory quality assurance are foundational to every precision treatment decision.\nEssential biomarkers and immunohistochemistry should be strengthened before indiscriminate expansion into complex testing.\nAfrican genomic data and multidisciplinary interpretation are needed to improve the relevance of molecular results.\nTesting has limited value when results cannot be linked to accessible treatment\, making financing and patient navigation part of precision care.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/implementing-precision-oncology-in-lmics/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-28-at-12.07.44-PM-3-e1785245724838.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260806T193000
DTEND;TZID=Africa/Nairobi:20260806T203000
DTSTAMP:20260820T224450Z
CREATED:20260820T224041Z
LAST-MODIFIED:20260820T224450Z
UID:41901-1786044600-1786048200@kesho-kenya.org
SUMMARY:Ovarian Cancer in Focus
DESCRIPTION:Ovarian Cancer in Focus: Innovation\, Care and Evolving Care\n\nModerator: Dr. Amina K. Habib\nSpeaker: Dr. Chris Gallagher\nDate: 6 August 2026\n\nSummary\nThis session examined recent developments in epithelial ovarian cancer\, from the continuing challenge of earlier diagnosis to surgical decision-making\, molecular stratification\, maintenance therapy and emerging options for recurrent and platinum-resistant disease. \nA central theme was the move towards increasingly biomarker-informed care. Dr. Chris Gallagher highlighted how BRCA1/2 mutations and homologous recombination deficiency are shaping treatment selection\, particularly PARP inhibitor maintenance after response to platinum-based chemotherapy. The discussion reinforced that these therapies offer the greatest value when matched to tumour biology rather than applied broadly. \nThe session also explored the challenge of finding ovarian cancer earlier. Emerging approaches using circulating DNA fragments may improve future detection\, but the evidence remains preliminary and requires wider validation. Surgical treatment was similarly framed around careful patient selection: the choice between upfront cytoreductive surgery and neoadjuvant chemotherapy should reflect disease extent\, patient fitness and the likelihood of achieving complete resection. \nFor recurrent and difficult-to-treat disease\, the discussion highlighted newer approaches including folate receptor alpha-targeted antibody-drug conjugates in platinum-resistant ovarian cancer and molecularly targeted strategies for low-grade serous disease. These developments are expanding treatment possibilities\, although the role of immunotherapy remains less clearly established. \nThe discussion brought these advances into the African context\, where access to BRCA and HRD testing\, targeted therapies and newer medicines remains uneven. Molecular testing is most meaningful when it can inform an accessible treatment pathway. In recurrent disease especially\, expected benefit must be weighed against toxicity\, quality of life\, patient fitness and financial burden. \nAcross the session\, a consistent message emerged: ovarian cancer care is becoming increasingly defined by tumour biology\, but improved outcomes still depend on appropriate surgery\, access to molecular testing\, careful patient selection and treatment pathways that reflect both evidence and real-world access. \nKey Takeaways\n\nEarlier detection remains a major unmet need\, with emerging circulating DNA approaches still requiring further validation.\nBRCA and homologous recombination status are increasingly important in guiding treatment selection.\nSurgical sequencing should be individualised\, with complete cytoreduction remaining an important treatment objective.\nPARP inhibitors and newer targeted therapies are expanding options for selected patients\, including those with recurrent or platinum-resistant disease.\nIn African settings\, clinical benefit\, treatment access\, affordability and quality of life must remain central to decision-making.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/ovarian-cancer-in-focus/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/Ovarian-Cancer-in-Focus-e1787265870600.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260813T193000
DTEND;TZID=Africa/Nairobi:20260813T203000
DTSTAMP:20260811T142645Z
CREATED:20260811T142028Z
LAST-MODIFIED:20260811T142645Z
UID:41876-1786649400-1786653000@kesho-kenya.org
SUMMARY:From Digital Diagnosis to Connected Cancer Care
DESCRIPTION:“From Digital Diagnosis to Connected Cancer Care” \nCPD ACCREDITED \nDate: 13th August 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker: Dr. Arvind Rao\nProfessor\, Department of Computational Medicine and Bioinformatics\, University of Michigan\nTalk: “From Digital Diagnosis to AI-Powered Cancer Care: Governance\, LLMs\, and the Connected Future” \nSpeaker: Dr. Joshua Kibera\nAnatomical Pathologist\, CEO/Founder – The Pathology Network\nTalk: “Beyond the Algorithm: Building the Digital Diagnostic Infrastructure for AI-Enabled Precision Cancer Care” \nModerator: Dr. Anne Korir\nSenior Research Scientist\, Kenya Medical Research Institute (KEMRI) \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/from-digital-diagnosis-to-connected-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/WhatsApp-Image-2026-08-11-at-10.35.44-AM-e1786457992618.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260602T074510Z
CREATED:20260407T183641Z
LAST-MODIFIED:20260602T074510Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-06-02-at-10.31.48-AM-e1780386294605.jpeg
END:VEVENT
END:VCALENDAR